DFN-11 (SUMATRIPTAN INJECTION)
Migraine With Aura
University of AarhusSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
20 Active assets in the Migraine With Aura cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topiramate Tongji Hospital | Phase 4 | BBB |
DHE Satsuma Pharmaceuticals, Inc. | Phase 3 | BB |
Apsolol Norwegian University of Science and Technology | Phase 3 | BB |
Rimegepant University of South Florida | Phase 4 | BB |
Almotriptan Messoud Ashina, MD | Phase 4 | BB |
View all 48 →
Same molecule, other indications
DFN-11 (SUMATRIPTAN INJECTION) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →